



Practitioner's Docket No. MP198-048CPICNIM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Goodearl, Andrew D. J., et al.
Application No.: 09/911,667 Group No.: 1655
Filed: July 24, 2001 Examiner: Not Yet Assigned
For: OC11p, A PROTEIN HAVING HOMOLOGU TO THE ORGANIC AND SUGAR
TRANSPORTER FAMILY OF PROTEINS, AND USES THEREOF

Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

1655
RECEIVED
PATENT CENTER MAY 23 2003
1600/2900

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed:

☒ Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

☐ After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Box 1450, Alexandria, Virginia 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

Diana Gentile
Signature

Date: May 20, 2003

Diana Gentile
(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI98-048CP1CN1M

☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).


FEE PAYMENT

3. ☐ The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

☒ Applicant believes no fee is due in connection with this submission, however, in the event any fee is due, please charge Deposit Account No. 501668.

May 20, 2003

MILLENNIUM PHARMACEUTICALS, INC.



Tracy M. Sioussat
Registration No. 50,609
75 Sidney Street
Cambridge, MA 02139
Telephone - (617) 374-7679
Facsimile - (617) 551-8820

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/911,667
Filing Date	July 24, 2001
First Named Inventor	Goodearl, Andrew D. J., et al
Group Art Unit	1655
Examiner Name	Not Yet Assigned
Attorney Docket Number	MP198-048CP1CN1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BG		JANZ, R. et al., "SV2 Related Protein," May 1, 1999 (sequence) TrEMBL: [online] Geneva, Switzerland: Swiss Institute of Bioinformatics [retrieved on September 26, 2002]. Retrieved from the Internet: <URL: http://www.expasy.ch >. TrEMBL Accession No. Q9Z217.	
BH		SULSTON, J. et al., "Hypothetical Protein ZK637.1 in Chromosome III," April 1, 1993 (sequence) Swiss Prot [online] Geneva, Switzerland: Swiss Institute of Bioinformatics [retrieved on September 26, 2002]. Retrieved from the Internet: <URL: http://www.expasy.ch >. Swiss Prot Accession No. P30638.	
BI		Martel, F. et al., "Transport of Small Organic Cations in the Rat Liver the Role of the Organic Cation Transporter OCT1." Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 354, No. 3, (1996), pp. 320-326.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231